ADA: Lilly Makes Its Case for Oral GLP-1 Orforglipron

ADA: Lilly makes its case for oral GLP-1 orforglipron

Lilly is on track to file its oral GLP-1 agonist orforglipron for type 2 diabetes next year after presenting the first phase 3 data with the drug.

‘Game changer’ diabetes pill a step closer after trials

Diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments such as Ozempic.

'Game changer' diabetes pill a step closer after trials

A new type of diabetes pill has been shown to act in a similar way to injectable treatments...

A pill instead of an injection? New GLP-1 pill shows promising results

A new drug, which can be taken as a pill and is in the same class of drugs as Ozempic, has shown promise for blood sugar control in clinical trials. The drug, orforglipron, is a glucagon-like peptide-1 (GLP-1) receptor agonist, which shows significant and clinically meaningful improvements in blood sugar control over 40 weeks and reduces body weight by up to 7.6%. The authors say the size of the effect on blood sugar was consistent with results …

ACHIEVE-1: Oral GLP-1 Agonist Orforglipron Shows Strong HbA1c, Weight Reductions

The ACHIEVE-1 trial reveals orforglipron's potential as a breakthrough treatment for type 2 diabetes.

Orforglipron Lowers A1c, Weight in Early Type 2 Diabetes

Phase 3 data support use of the oral non-peptide small molecule as potential first-line type 2 diabetes treatment, investigator says. Medscape Medical News